Trials / Unknown
UnknownNCT05812430
Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer
The Efficacy and Safety of Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- The First Affiliated Hospital of Zhengzhou University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of anlotinib plus TQB2450 combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | anlotinib+TQB2450+nab-paclitaxel+cisplatin | Anlotinib: 10mg, po, d1\~14, q3w, until disease progression or unacceptable toxicity. TQB2450: 1200mg, ivgtt, d1, q3w, until disease progression or unacceptable toxicity. nab-paclitaxel: 200mg/㎡, ivgtt, d1, q3w, 6 cycles. cisplatin: 60mg/㎡, ivgtt, d1, q3w, 6 cycles. |
Timeline
- Start date
- 2023-04-10
- Primary completion
- 2023-10-10
- Completion
- 2024-10-10
- First posted
- 2023-04-13
- Last updated
- 2023-09-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05812430. Inclusion in this directory is not an endorsement.